Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease.
http://news.yahoo.com/abbott-labs-rises-hepatitis-c-drug-data-154902947--finance.html
http://news.yahoo.com/abbott-labs-rises-hepatitis-c-drug-data-154902947--finance.html